Is 10X Genomics Stock a Good Investment?

10X Genomics Investment Advice

  TXG
To provide specific investment advice or recommendations on 10X Genomics stock, we recommend investors consider the following general factors when evaluating 10X Genomics. This will help you to make an informed decision on whether to include 10X Genomics in one of your diversified portfolios:
  • Examine 10X Genomics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
  • Research 10X Genomics' leadership team and their track record. Good management can help 10X Genomics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
  • Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact 10X Genomics' business and its evolving consumer preferences.
  • Compare 10X Genomics' performance and market position to its competitors. Analyze how 10X Genomics is positioned in terms of product offerings, innovation, and market share.
  • Check if 10X Genomics pays a dividend and its dividend yield and payout ratio.
  • Review what financial analysts are saying about 10X Genomics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in 10X Genomics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if 10X Genomics is a good investment.
 
Sell
 
Buy
Strong Hold
Our trade advice tool can cross-verify current analyst consensus on 10X Genomics and to analyze the company potential to grow this quarter and beyond. To make sure 10X Genomics is not overpriced, please confirm all 10X Genomics fundamentals, including its cash flow from operations, and the relationship between the cash per share and number of employees . Given that 10X Genomics has a number of shares shorted of 14.81 M, we suggest you to validate 10X Genomics market performance and probability of bankruptcy to ensure the company can sustain itself this quarter and beyond given your prevailing risk tolerance and investing horizon.

Market Performance

SolidDetails

Volatility

Somewhat reliableDetails

Hype Condition

StaleDetails

Current Valuation

OvervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Actively responds to the marketDetails

Investor Sentiment

ImpartialDetails

Analyst Consensus

BuyDetails

Financial Leverage

Not RatedDetails

Reporting Quality (M-Score)

UnavailableDetails

Examine 10X Genomics Stock

Researching 10X Genomics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The book value of 10X Genomics was at this time reported as 5.74. The company has Price/Earnings To Growth (PEG) ratio of 0.13. 10X Genomics recorded a loss per share of 1.3. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 17th of July 2006.
To determine if 10X Genomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 10X Genomics' research are outlined below:
10X Genomics appears to be risky and price may revert if volatility continues
The company reported the last year's revenue of 610.78 M. Reported Net Loss for the year was (182.63 M) with profit before taxes, overhead, and interest of 427.01 M.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Is Fate Therapeutics Inc. a good long term investment - High-yield investments - Jammu Links News
10X Genomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 10X Genomics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 10X Genomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
15th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View
Earnings surprises can significantly impact 10X Genomics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises 10X Genomics' investors have experienced.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-02-13
2024-12-31-0.1067-0.1356-0.028927 
2024-10-29
2024-09-30-0.34-0.30.0411 
2020-02-18
2019-12-31-0.11-0.070.0436 
2024-02-15
2023-12-31-0.36-0.41-0.0513 
2021-11-03
2021-09-30-0.2-0.150.0525 
2019-09-11
2019-06-30-0.11-0.16-0.0545 
2023-05-03
2023-03-31-0.37-0.44-0.0718 
2022-05-04
2022-03-31-0.31-0.38-0.0722 

Know 10X Genomics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as 10X Genomics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 10X Genomics backward and forwards among themselves. 10X Genomics' institutional investor refers to the entity that pools money to purchase 10X Genomics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Ra Capital Management, Llc2025-03-31
1.9 M
Geode Capital Management, Llc2025-03-31
1.9 M
State Street Corp2025-03-31
1.8 M
Two Sigma Advisers, Llc2025-03-31
1.7 M
Assenagon Asset Management Sa2025-06-30
1.7 M
Voloridge Investment Management, Llc2025-03-31
1.6 M
Deerfield Management Co2025-03-31
1.5 M
Capital World Investors2025-03-31
1.5 M
Two Sigma Investments Llc2025-03-31
1.4 M
Ark Investment Management Llc2025-03-31
12.8 M
Vanguard Group Inc2025-03-31
11.1 M
Note, although 10X Genomics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

10X Genomics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a total capitalization of 1.68 B.

Market Cap

5.23 Billion

10X Genomics' profitablity analysis

Last ReportedProjected for Next Year
Return On Tangible Assets(0.20)(0.21)
Return On Capital Employed(0.24)(0.26)
Return On Assets(0.20)(0.21)
Return On Equity(0.26)(0.27)
The company has Net Profit Margin of (0.25) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.31) %, which entails that for every $100 of revenue, it lost $0.31.
Determining 10X Genomics' profitability involves analyzing its financial statements and using various financial metrics to determine if 10X Genomics is a good buy. For example, gross profit margin measures 10X Genomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 10X Genomics' profitability and make more informed investment decisions.

10X Genomics' Earnings Breakdown by Geography

Evaluate 10X Genomics' management efficiency

10X Genomics has Return on Asset of (0.1243) % which means that on every $100 spent on assets, it lost $0.1243. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2203) %, meaning that it generated no profit with money invested by stockholders. 10X Genomics' management efficiency ratios could be used to measure how well 10X Genomics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.21. The current Return On Capital Employed is estimated to decrease to -0.26. At this time, 10X Genomics' Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The 10X Genomics' current Debt To Assets is estimated to increase to 0.12, while Non Current Assets Total are projected to decrease to roughly 230.2 M.
Last ReportedProjected for Next Year
Book Value Per Share 5.90  6.19 
Tangible Book Value Per Share 5.73  6.01 
Enterprise Value Over EBITDA(10.96)(11.51)
Price Book Value Ratio 2.44  2.31 
Enterprise Value Multiple(10.96)(11.51)
Price Fair Value 2.44  2.31 
Enterprise Value5.7 BB
The management strategies employed by 10X Genomics' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta
2.028

Basic technical analysis of 10X Stock

As of the 24th of July, 10X Genomics shows the mean deviation of 3.01, and Coefficient Of Variation of 399.68. Compared to fundamental indicators, the technical analysis model gives you tools to check timely technical drivers of 10X Genomics, as well as the relationship between them. Please confirm 10X Genomics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if 10X Genomics is priced more or less accurately, providing market reflects its regular price of 13.62 per share. Given that 10X Genomics has jensen alpha of 0.5886, we suggest you to validate 10X Genomics's prevailing market performance to make sure the company can sustain itself sooner or later.

10X Genomics' insider trading activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 10X Genomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on 10X Genomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 10X Genomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

10X Genomics' Outstanding Corporate Bonds

10X Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 10X Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most 10X bonds can be classified according to their maturity, which is the date when 10X Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Understand 10X Genomics' technical and predictive indicators

Using predictive indicators to make investment decisions involves analyzing 10X Genomics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.

Consider 10X Genomics' intraday indicators

10X Genomics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of 10X Genomics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

10X Genomics Corporate Filings

16th of July 2025
Other Reports
ViewVerify
F4
11th of June 2025
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
5th of June 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
10Q
9th of May 2025
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
10X Genomics time-series forecasting models is one of many 10X Genomics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary 10X Genomics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

10X Stock media impact

There is far too much social signal, news, headlines, and media speculation about 10X Genomics that are available to investors today. This information is accessible both publicly - through 10X Genomics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of 10X-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of 10X Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 10X Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 10X Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 10X Genomics alpha.

10X Genomics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards 10X Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

10X Genomics Historical Investor Sentiment

Investor biases related to 10X Genomics' public news can be used to forecast risks associated with an investment in 10X. The trend in average sentiment can be used to explain how an investor holding 10X can time the market purely based on public headlines and social activities around 10X Genomics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
10X Genomics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for 10X Genomics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average 10X Genomics news discussions. The higher the estimate score, the more favorable the investor's outlook on 10X Genomics.

10X Genomics Maximum Pain Price Across September 19th 2025 Option Contracts

10X Genomics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of 10X Genomics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of 10X Genomics' options.

10X Genomics Corporate Management

When determining whether 10X Genomics is a strong investment it is important to analyze 10X Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact 10X Genomics' future performance. For an informed investment choice regarding 10X Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in 10X Genomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 10X Genomics. If investors know 10X will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 10X Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.30)
Revenue Per Share
5.152
Quarterly Revenue Growth
0.098
Return On Assets
(0.12)
Return On Equity
(0.22)
The market value of 10X Genomics is measured differently than its book value, which is the value of 10X that is recorded on the company's balance sheet. Investors also form their own opinion of 10X Genomics' value that differs from its market value or its book value, called intrinsic value, which is 10X Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 10X Genomics' market value can be influenced by many factors that don't directly affect 10X Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between 10X Genomics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if 10X Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 10X Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.